Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02468778 · ClinicalTrials.gov registry record · NA

SHIELD II Clinical Investigation

A NA study, sponsored by Abbott Medical Devices.

Terminated
Registry status
NA
Development phase
54
Enrollment target

NCT02468778 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 54 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02468778, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.

TERMINATED
Registry status
NA
Development phase
54 participants
Enrollment target

Study Summary

The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.

Interventions

  • DEVICE HeartMate PHP
  • DEVICE Any Abiomed Impella® device approved for use in high-risk PCI

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2015-08
Est. Completion 2021-05-17
Phase NA

Sponsor

Abbott Medical Devices

261 total trials

What the Registry Record Tells You About NCT02468778

The ClinicalTrials.gov registry entry for NCT02468778 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which HeartMate PHP is the first listed.

NCT02468778 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02468778 about?

NCT02468778 is a clinical study titled "SHIELD II Clinical Investigation". The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac s...

What is the current status of trial NCT02468778?

This trial is currently terminated. It is a NA study. The enrollment target is 54 participants. The study started on 2015-08. Estimated completion is 2021-05-17.

What interventions are being tested in trial NCT02468778?

The interventions under investigation include: HeartMate PHP (DEVICE), Any Abiomed Impella® device approved for use in high-risk PCI (DEVICE).

Who is sponsoring clinical trial NCT02468778?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.